Fig. 2From: Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatmentMeta-analysis forest plot with a fixed-effect model showing the partial response rate (PRR), which is 23 % with a 95 % CI of 17–31 %. The total number of individuals included in the analysis was 156. I2 = 52.6 %. The random-effects model estimated a PRR of 24.5 % (95 % CI, 14.5–38.4 %)Back to article page